In order to make a comparison about the similarity of the expression profiles between previous melanoma patients with detailed immunotherapeutic information and the SLC11A1 subgroups of glioma patients, we also utilized the submap algorithm, which demonstrated that the patients in the SLC11A1-high subgroup were more reactive to anti-PD-1 and anti-CTLA4 treatment (Figure 7D) (28). The gene discussed is PDCD1; the disease is central nervous system cancer.